These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 29327175)

  • 1. MicroRNA-30c as a novel diagnostic biomarker for primary and secondary B-cell lymphoma of the CNS.
    Baraniskin A; Chomiak M; Ahle G; Gress T; Buchholz M; Turewicz M; Eisenacher M; Margold M; Schlegel U; Schmiegel W; Hahn S; Schroers R
    J Neurooncol; 2018 May; 137(3):463-468. PubMed ID: 29327175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system.
    Baraniskin A; Kuhnhenn J; Schlegel U; Chan A; Deckert M; Gold R; Maghnouj A; Zöllner H; Reinacher-Schick A; Schmiegel W; Hahn SA; Schroers R
    Blood; 2011 Mar; 117(11):3140-6. PubMed ID: 21200023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Study on the Clinicopathologic and Molecular Characteristics of Primary and Secondary Diffuse Large B-cell Lymphoma in the Central Nervous System.
    DO J; Yenwongfai LN; DO SI; Kim SW; Na K
    Anticancer Res; 2024 Jul; 44(7):2953-2960. PubMed ID: 38925823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MYD88 L265P mutation and interleukin-10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: results from a prospective study.
    Ferreri AJM; Calimeri T; Lopedote P; Francaviglia I; Daverio R; Iacona C; Belloni C; Steffanoni S; Gulino A; Anghileri E; Diffidenti A; Finardi A; Gagliardi F; Anzalone N; Nonis A; Furlan R; De Lorenzo D; Terreni MR; Martinelli V; Sassone M; Foppoli M; Angelillo P; Guggiari E; Falini A; Mortini P; Filippi M; Tarantino V; Eoli M; Ciceri F; Doglioni C; Tripodo C; Locatelli M; Cangi MG; Ponzoni M
    Br J Haematol; 2021 May; 193(3):497-505. PubMed ID: 33620087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Performance status, comorbidities, and cycles of methotrexate exert the greatest influence on outcomes of primary and secondary CNS lymphomas: the Lexington experience.
    Curry LD; Munker R; Li N; Yan D; Pryor P; Nozad S; Keller P; Monohan GP; Iragavarapu C; Krem MM
    Ann Hematol; 2023 Jan; 102(1):141-154. PubMed ID: 36367559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epstein-Barr virus DNA load in cerebrospinal fluid and plasma of patients with AIDS-related lymphoma.
    Bossolasco S; Cinque P; Ponzoni M; Vigano MG; Lazzarin A; Linde A; Falk KI
    J Neurovirol; 2002 Oct; 8(5):432-8. PubMed ID: 12402169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNAs in cerebrospinal fluid as biomarker for disease course monitoring in primary central nervous system lymphoma.
    Baraniskin A; Kuhnhenn J; Schlegel U; Schmiegel W; Hahn S; Schroers R
    J Neurooncol; 2012 Sep; 109(2):239-44. PubMed ID: 22729947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Results of combined-modality therapy for primary and secondary malignant lymphoma of the central nervous system (CNS).
    Kawamura T; Koga S; Okamoto M; Kanno T; Iwamura H
    Radiat Med; 2001; 19(3):145-9. PubMed ID: 11467381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating U2 small nuclear RNA fragments as a novel diagnostic biomarker for primary central nervous system lymphoma.
    Baraniskin A; Zaslavska E; Nöpel-Dünnebacke S; Ahle G; Seidel S; Schlegel U; Schmiegel W; Hahn S; Schroers R
    Neuro Oncol; 2016 Mar; 18(3):361-7. PubMed ID: 26250566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor and Cerebrospinal Fluid microRNAs in Primary Central Nervous System Lymphomas.
    Zajdel M; Rymkiewicz G; Sromek M; Cieslikowska M; Swoboda P; Kulinczak M; Goryca K; Bystydzienski Z; Blachnio K; Ostrowska B; Borysiuk A; Druzd-Sitek A; Walewski J; Chechlinska M; Siwicki JK
    Cancers (Basel); 2019 Oct; 11(11):. PubMed ID: 31731456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of the Diagnostic Utility of Serum MicroRNA Classification in Patients With Diffuse Glioma.
    Ohno M; Matsuzaki J; Kawauchi J; Aoki Y; Miura J; Takizawa S; Kato K; Sakamoto H; Matsushita Y; Takahashi M; Miyakita Y; Ichimura K; Narita Y; Ochiya T
    JAMA Netw Open; 2019 Dec; 2(12):e1916953. PubMed ID: 31808923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum miR-21 is a diagnostic and prognostic marker of primary central nervous system lymphoma.
    Mao X; Sun Y; Tang J
    Neurol Sci; 2014 Feb; 35(2):233-8. PubMed ID: 23832112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toxicity and efficacy of CAR T-cell therapy in primary and secondary CNS lymphoma: a meta-analysis of 128 patients.
    Cook MR; Dorris CS; Makambi KH; Luo Y; Munshi PN; Donato M; Rowley S; Saad A; Goy A; Dunleavy K; Ali A
    Blood Adv; 2023 Jan; 7(1):32-39. PubMed ID: 36260735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Set of 17 microRNAs Common for Brain and Cerebrospinal Fluid Differentiates Primary Central Nervous System Lymphoma from Non-Malignant Brain Tumors.
    Sromek M; Rymkiewicz G; Paziewska A; Szafron LM; Kulecka M; Zajdel M; Kulinczak M; Dabrowska M; Balabas A; Bystydzienski Z; Chechlinska M; Siwicki JK
    Biomolecules; 2021 Sep; 11(9):. PubMed ID: 34572608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Soluble TACI and soluble BCMA as biomarkers in primary central nervous system lymphoma.
    Thaler FS; Laurent SA; Huber M; Mulazzani M; Dreyling M; Ködel U; Kümpfel T; Straube A; Meinl E; von Baumgarten L
    Neuro Oncol; 2017 Nov; 19(12):1618-1627. PubMed ID: 28521029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic value of interleukin-10 in cerebrospinal fluid for diffuse large B-cell lymphoma of the central nervous system.
    Sasagawa Y; Akai T; Tachibana O; Iizuka H
    J Neurooncol; 2015 Jan; 121(1):177-83. PubMed ID: 25258254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Similar chemokine receptor profiles in lymphomas with central nervous system involvement - possible biomarkers for patient selection for central nervous system prophylaxis, a retrospective study.
    Lemma SA; Pasanen AK; Haapasaari KM; Sippola A; Sormunen R; Soini Y; Jantunen E; Koivunen P; Salokorpi N; Bloigu R; Turpeenniemi-Hujanen T; Kuittinen O
    Eur J Haematol; 2016 May; 96(5):492-501. PubMed ID: 26153511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical features and treatment outcomes of isolated secondary central nervous system lymphomas in Miyazaki Prefecture.
    Kawano N; Ochiai H; Yoshida S; Yamashita K; Shide K; Shimoda H; Hidaka T; Kubuki Y; Katayose K; Toyama T; Kawano H; Matsuoka H; Ishizaki J; Maeda K; Satou S; Yano T; Yamaguchi K; Takenaka K; Shimao Y; Oshima K; Ueda A; Shimoda K
    Int J Clin Oncol; 2012 Aug; 17(4):336-40. PubMed ID: 21904968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CSF neopterin level as a diagnostic marker in primary central nervous system lymphoma.
    Viaccoz A; Ducray F; Tholance Y; Barcelos GK; Thomas-Maisonneuve L; Ghesquières H; Meyronet D; Quadrio I; Cartalat-Carel S; Louis-Tisserand G; Jouanneau E; Guyotat J; Honnorat J; Perret-Liaudet A
    Neuro Oncol; 2015 Nov; 17(11):1497-503. PubMed ID: 26014047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current strategies in the diagnosis of diffuse large B-cell lymphoma of the central nervous system.
    Baraniskin A; Deckert M; Schulte-Altedorneburg G; Schlegel U; Schroers R
    Br J Haematol; 2012 Feb; 156(4):421-32. PubMed ID: 22077417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.